Drugs / Manzi Guben granules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05722093 | Jun 2023 → May 2026 | COVID-19 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Manzi Guben granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05722093 ↗ |
| Known as | Manzhi Guben granules | “the main components of Manzhi Guben granules (Yupingfeng + Angelica sinensis) are:” NCT05722093 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Chinese patent medicine” NCT05722093 ↗ |